101 Therapeutics Publicly Releases Clinical and Scientific Data for Macrophage-Targeted Anti-Inflammatory Candidate as It Seeks Urgent Review for Bundibugyo Ebola Outbreak Use
101 Therapeutics Ltd. has publicly released a broad package of clinical and scientific evidence for its investigational therapy 101-PGC-005, a macrophage-targeted dexamethasone prodrug designed to suppress harmful inflammatory activity in CD206-positive macrophages while aiming to preserve broader systemic immune function. The company said the decision to disclose the data now reflects the urgency of the ongoing Bundibugyo virus disease outbreak in the Democratic Republic of the Congo and Uganda, where there are currently no approved vaccines or species-specific therapies for the Ebola virus species involved.
The release marks the first public disclosure of detailed clinical documentation for the program, which 101 Therapeutics believes could have relevance in severe infectious hyperinflammatory conditions beyond its original development context. To support broader review, the company has posted a clinical manuscript as a preprint on medRxiv and published a scientific white paper on its website focused specifically on the potential relevance of 101-PGC-005 to Bundibugyo virus disease, a form of Ebola disease caused by Orthoebolavirus bundibugyoense.
According to the company, the objective of releasing the information before peer-reviewed publication is not to circumvent scientific scrutiny, but rather to accelerate evaluation by the clinicians, regulators, public health authorities, ethics committees, and potential development partners who would need to assess whether the therapy merits emergency clinical investigation during an active outbreak. 101 Therapeutics argues that in a setting where patients are facing a life-threatening disease with no approved Bundibugyo-specific countermeasures, waiting for the standard pace of academic publication could delay consideration of a potentially relevant host-directed therapeutic strategy.
Company Seeks Rapid Scientific and Regulatory Review
Dr. Michael Goldberg, Founder and Chief Scientific Officer of 101 Therapeutics, said the company remains committed to the peer-review process and is actively pursuing formal publication. At the same time, he emphasized that the timeline of an active Ebola outbreak does not align well with the normal pace of academic review and journal publication.
Goldberg said the company’s intention is to put the data directly in front of qualified experts who can evaluate the evidence critically and determine whether emergency clinical assessment is warranted. That includes examining the proposed mechanism of action, challenging the biological rationale, reviewing the safety profile, and assessing whether the existing human data justify moving the candidate into outbreak-related study settings.
The company’s message is cautious but urgent. 101 Therapeutics is not claiming that 101-PGC-005 has been proven effective in Ebola virus disease. Instead, it is arguing that the combination of mechanistic rationale, human clinical experience in severe infectious hyperinflammation, and the absence of approved Bundibugyo-specific therapies creates a sufficiently compelling case for rapid independent review.
A Major Unmet Need in Bundibugyo Ebola Virus Disease
The company’s announcement is rooted in the treatment gap surrounding Bundibugyo virus disease. Unlike Zaire ebolavirus, which has approved vaccines and monoclonal antibody therapies available in certain settings, Bundibugyo virus disease currently lacks an approved vaccine, species-specific antibody treatment, or antiviral therapy. As a result, care remains largely supportive, focused on hydration, symptom management, hemodynamic support, and treatment of complications rather than on a pathogen-targeted intervention.
That gap is especially important because Ebola virus disease can involve not only direct viral injury but also profound inflammatory dysregulation. In severe cases, patients may experience a cascade of immune activation, vascular injury, capillary leak, organ dysfunction, and shock. 101 Therapeutics believes that this inflammatory component creates a rationale for exploring host-directed therapies that do not directly target the virus itself, but instead modulate the damaging immune responses that contribute to severe disease and mortality.
The company argues that this unmet need justifies urgent consideration of approaches capable of selectively dampening harmful inflammation without broadly suppressing the immune system’s ability to fight infection. That is where 101-PGC-005 is positioned.
A Macrophage-Targeted Approach to Severe Inflammation
101-PGC-005 is described as a macrophage-targeted dexamethasone prodrug engineered to deliver dexamethasone intracellularly to activated CD206-positive macrophages. These macrophages are implicated in severe inflammatory amplification across a range of infectious and noninfectious hyperinflammatory conditions. By directing the anti-inflammatory payload specifically toward these cells, the company hopes to blunt the most harmful inflammatory signaling while avoiding the systemic glucocorticoid exposure associated with standard corticosteroid therapy.
This distinction is central to 101 Therapeutics’ scientific hypothesis. Conventional corticosteroids such as dexamethasone can be highly effective anti-inflammatory agents, but their use in infectious disease settings can raise concerns because they may also suppress protective immune responses if delivered broadly throughout the body. In viral diseases, that balance is particularly delicate. Excessive inflammation can be lethal, but so can impairing the body’s ability to control viral replication.
The company believes that selectively targeting activated macrophages may offer a way to modulate pathogenic inflammation while preserving systemic antiviral immune function. In other words, the goal is not generalized immunosuppression, but focused intervention against a specific inflammatory driver.
101 Therapeutics says that the potential relevance of this approach to Bundibugyo Ebola lies in the role macrophages may play in the progression of severe viral inflammatory syndromes. Activated macrophages are thought to contribute to vascular damage, cytokine amplification, immune dysregulation, and organ injury in a variety of acute inflammatory states. If that biology is also important in Bundibugyo Ebola virus disease, then a macrophage-directed anti-inflammatory strategy could, in theory, be worth testing.
What the Company Says Justifies Urgent Review
Although the company stops short of claiming efficacy in Ebola, it has outlined several reasons why it believes 101-PGC-005 should be urgently evaluated by relevant stakeholders. These include:
- Human clinical data in severe infectious hyperinflammation
- Evidence of preserved hypothalamic-pituitary-adrenal (HPA) axis function
- Human pharmacokinetic findings showing no detectable systemic free dexamethasone exposure
- A mechanistic rationale tied to macrophage-driven inflammatory pathology
- The absence of approved Bundibugyo-specific vaccines or therapeutics
Taken together, 101 Therapeutics argues that these elements support the case for rapid review by regulators, ethics committees, outbreak clinicians, Ministries of Health, and potential development partners. The company is also seeking attention from public health agencies, funders, and biopharmaceutical collaborators who could help determine whether emergency clinical evaluation is feasible.
Clinical Evidence Package Centers on Phase II/III COVID-19 Trial
At the heart of the newly released evidence package is a Phase II/III adaptive randomized controlled trial involving 309 hospitalized patients with severe COVID-19-associated inflammatory disease. The study is described in a medRxiv manuscript titled “Macrophage-targeted glucocorticoid prodrug resolves acute inflammation while preserving HPA-axis function: mechanistic, preclinical, and Phase II/III clinical evidence” authored by Goldberg and colleagues in 2026.
The company presents this COVID-19 trial as a proof-of-concept for the host-directed inflammatory mechanism rather than as a virus-specific efficacy study. In 101 Therapeutics’ view, the relevance of the data lies in the fact that the treatment was evaluated in a setting of severe infectious hyperinflammation, where activated macrophages are thought to play an important pathogenic role.
According to the company, the randomized study used a fixed three-dose regimen of 101-PGC-005 across the trial population, including patients with pre-existing medical conditions and concomitant medications. 101 Therapeutics said that all patients randomized to the investigational therapy were discharged without the need for rescue immunomodulatory therapy beyond the fixed treatment course. The company estimates that this effectively spared approximately 30 to 36 mg of cumulative systemic dexamethasone exposure that otherwise might have been required over the course of treatment.
The company further states that in the study, 101-PGC-005 demonstrated superiority over dexamethasone on the primary endpoint and multiple secondary endpoints. While the announcement does not detail each endpoint in full, the framing suggests that the company views the results as evidence that targeted intracellular delivery of dexamethasone to macrophages may outperform conventional systemic dexamethasone in a severe inflammatory infectious setting.
Safety and Endocrine Findings Highlighted by the Company
In addition to efficacy, 101 Therapeutics is emphasizing several safety and pharmacology findings that it believes differentiate 101-PGC-005 from standard systemic corticosteroid treatment.
The company reports that there were zero patient dropouts in the randomized trial and no treatment-related serious adverse events. It also highlights preservation of HPA-axis function, a notable point because systemic corticosteroids can suppress the body’s endogenous steroid regulatory system. If confirmed, preserved HPA-axis function would suggest that the investigational prodrug may avoid one of the more important physiological consequences of systemic glucocorticoid exposure.
Another key element of the evidence package is the pharmacokinetic profile. According to 101 Therapeutics, human PK studies showed no detectable systemic release of free dexamethasone in plasma, urine, or cerebrospinal fluid. That claim is central to the company’s argument that the therapy may deliver anti-inflammatory benefit without the broad systemic steroid exposure associated with traditional dexamethasone dosing.
The company also said that preclinical toxicology data support further clinical development, adding another layer to the package being presented for review.
Why the Company Believes the COVID Data Could Matter Beyond COVID-19
A major question raised by the announcement is whether data from severe COVID-19 can reasonably inform the evaluation of a therapy for Ebola virus disease. 101 Therapeutics’ answer is that 101-PGC-005 is not being advanced as a virus-specific antiviral but as a pathogen-agnostic, host-directed therapeutic platform for infectious cytokine storm syndromes.
In the company’s view, the trial’s relevance extends beyond SARS-CoV-2 because the therapeutic mechanism targets a host inflammatory pathway rather than a viral protein or replication step. If severe disease in multiple infections shares common features—such as activated macrophage signaling, vascular inflammation, immune dysregulation, and organ failure—then a therapy that modulates that host response might have utility across more than one infectious condition.
That is the conceptual bridge the company is trying to build between COVID-19-associated hyperinflammation and Bundibugyo Ebola virus disease. The company acknowledges that this does not constitute proof of efficacy in Ebola, but argues that the biological overlap is strong enough to justify emergency clinical evaluation rather than waiting for years of traditional development sequencing.
Direct Appeal to Public Health and Outbreak Stakeholders
101 Therapeutics said it is intentionally broadening its disclosure strategy so the evidence can be reviewed not only by journal editors and peer reviewers, but also by the institutions that would need to make decisions during an outbreak. The company specifically said the release is intended to support evaluation by outbreak clinicians, treatment centers, Ministries of Health in affected or at-risk countries, regulators, ethics committees, and public health organizations such as the World Health Organization, CDC, BARDA, ASPR, and NIAID.
The company is also seeking engagement from pharmaceutical and biotechnology partners, global health funders, and investors who might be able to support the next steps required for emergency evaluation. Those next steps could include additional translational work, protocol design, regulatory interactions, manufacturing scale-up, and logistical planning for outbreak deployment.
In effect, 101 Therapeutics is trying to move the conversation beyond the standard biotech pattern of “publish first, discuss later.” Instead, it is using preprint publication and white-paper disclosure as a way to start simultaneous scientific, regulatory, and operational discussions while peer review is still ongoing.
Field Use Considerations and Outbreak Logistics
Beyond the clinical rationale, the company also highlighted practical considerations relevant to outbreak response. 101-PGC-005 is described as a lyophilized small molecule that can be reconstituted in normal saline and administered by injection. 101 Therapeutics believes that this formulation, combined with a short-course dosing strategy, may be compatible with the realities of field deployment in outbreak settings.
That does not mean the product is ready for immediate use. The company explicitly notes that any deployment would still require regulatory review, supply-chain validation, and country-specific authorization. However, by emphasizing storage profile and dosing simplicity, 101 Therapeutics is signaling that the candidate may have logistical advantages compared with more complex biologic therapies, especially in resource-constrained environments where cold chain, infusion infrastructure, and repeated dosing can be major barriers.
The company said it is prepared to provide detailed data packages to qualified regulatory authorities, research institutions, pharmaceutical partners, and outbreak-response organizations under appropriate confidentiality and data-sharing arrangements. That suggests 101 Therapeutics is actively inviting structured due diligence rather than merely publishing the data for public visibility.
A Bid to Turn an Investigational Program Into an Emergency Evaluation Candidate
Ultimately, 101 Therapeutics’ announcement is an attempt to reposition 101-PGC-005 from a relatively little-known investigational anti-inflammatory program into a candidate worthy of urgent outbreak-related review. The company is not presenting the therapy as an approved or validated Ebola treatment. Instead, it is making a narrower but still ambitious case: that the combination of clinical data in severe infectious hyperinflammation, macrophage-targeting biology, limited systemic steroid exposure, and the absence of Bundibugyo-specific therapies should be enough to trigger immediate scrutiny by the people capable of launching emergency evaluation.
Whether that argument gains traction will depend on how regulators, clinicians, and infectious disease experts assess the evidence package. They will need to weigh the strength of the COVID-19 data, the plausibility of the mechanistic link to Ebola pathophysiology, the safety profile, and the feasibility of rapidly designing an ethically and operationally sound study in outbreak conditions.
For now, 101 Therapeutics has chosen to put its data into the public domain and invite that scrutiny. In doing so, the company is betting that the urgency of Bundibugyo virus disease, combined with the lack of approved species-specific interventions, creates a rare moment in which a host-directed anti-inflammatory strategy could move from preprint and white paper to serious outbreak-response consideration much faster than under normal development timelines.
About 101 Therapeutics
101 Therapeutics Ltd. is a biopharmaceutical company developing macrophage-targeted therapeutics for acute and chronic inflammatory diseases. Its lead program, 101-PGC-005, is a Type 1a dexamethasone prodrug engineered for selective CD206-positive macrophage uptake and intracellular release, with the goal of preserving systemic cortisol physiology while modulating pathogenic inflammatory macrophage activity.
101-PGC-005 has received FDA Rare Pediatric Disease Designation for systemic juvenile idiopathic arthritis flares and is being developed across rare inflammatory diseases, cytokine-release syndromes, and infectious cytokine storm indications.
